Literature DB >> 18698265

Are acquired hepatocerebral degeneration and hepatic myelopathy reversible?

Binnur Pinarbasi1, Sabahattin Kaymakoglu, Zeliha Matur, Filiz Akyuz, Kadir Demir, Fatih Besisik, Sadakat Ozdil, Gungor Boztas, Yilmaz Cakaloglu, Zeynel Mungan, Atilla Okten.   

Abstract

BACKGROUND: Acquired hepatocerebral degeneration (AHD) and hepatic myelopathy (HM) are rare complications of chronic liver disease and are usually resistant to medical therapy.
MATERIALS AND METHODS: The clinical and laboratory findings of 14 male and 2 female patients with AHD or HM were evaluated.
RESULTS: The prevalence of AHD and HM was 2% inpatient case series in the last 10 years. The median age of the patients (5 Child's B and 11 Child's C) was 48.7 years (28 to 66 y), and the mean known duration of the liver disease was 75 months (24 to 194 mo). The median time of onset of neurologic findings after diagnosis of the liver disease was 14.5 months. Eight patients who had marked spastic paraparesis or tetraparesis were included in the HM group and all others had AHD group. Sixty-nine percent of the patients had a spontaneous or surgical portosystemic shunts, and the remaining dense retroperitoneal collaterals. During the follow-up period of median 29 months (4 to 72 mo), 12 patients died while waiting for liver transplantation, and these patients suffered from the several complications of chronic liver disease more than the living patients. A marked improvement was observed in 2 of the patients (1 with AHD and the other with HM) at 6 and 8 months after the liver transplantation, respectively.
CONCLUSIONS: Our data suggest that liver transplantation had an important effect on the improvement in these patients.

Entities:  

Mesh:

Year:  2009        PMID: 18698265     DOI: 10.1097/MCG.0b013e318150d399

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  12 in total

Review 1.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

2.  Atypical neurological disorders in an elderly man with liver cirrhosis.

Authors:  Guerino Recinella; Giovanni Serafini; Donatella Magalotti; Marco Zoli
Journal:  Aging Clin Exp Res       Date:  2019-07-26       Impact factor: 3.636

Review 3.  Challenges in diagnosing hepatic encephalopathy.

Authors:  K Weissenborn
Journal:  Neurochem Res       Date:  2014-08-21       Impact factor: 3.996

4.  Chronic acquired hepatocerebral degeneration: effects of liver transplantation on neurological manifestations.

Authors:  A Stracciari; E Baldin; L Cretella; L Delaj; R D'Alessandro; M Guarino
Journal:  Neurol Sci       Date:  2011-02-17       Impact factor: 3.307

5.  Acquired Hepatocerebral Degeneration After a Splenorenal Shunt in the Sub-Saharan Africa Context: A Case Report and Brief Review of Literature.

Authors:  Abdu Mohammed; Abate Bane; Getahun Mengistu; Fekadu Ayalew; Amir Sultan Seid
Journal:  Cureus       Date:  2022-03-11

6.  Acquired hepatocerebral degeneration: A case report.

Authors:  Clarice Listik; Gislaine Cristina Lopes Machado-Porto; Maira Okada de Oliveira; Fábio Henrique de Gobbi Porto
Journal:  Dement Neuropsychol       Date:  2012 Jan-Mar

7.  Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients.

Authors:  Elisa Maffeo; Anna Montuschi; Guido Stura; Maria Teresa Giordana
Journal:  Neurol Sci       Date:  2013-05-28       Impact factor: 3.307

8.  Chronic acquired hepatocerebral degeneration presenting with Meige's syndrome and behavioral symptoms fully reversed by liver transplantation.

Authors:  Andrea Stracciari; Luca Spinardi; Maria Guarino
Journal:  Neurol Sci       Date:  2021-07-19       Impact factor: 3.307

Review 9.  Spinal cord involvement in patients with cirrhosis.

Authors:  Raffaele Nardone; Yvonne Höller; Monica Storti; Piergiorgio Lochner; Frediano Tezzon; Stefan Golaszewski; Francesco Brigo; Eugen Trinka
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 10.  Parkinsonism in cirrhosis: pathogenesis and current therapeutic options.

Authors:  Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2012-10-20       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.